Performing a Low-dose, Whole-body Angiography as the First Element of an Imaging Assessment Following Stroke / TIA

Inclusion Criteria: * The patient was informed about the implementation of the study, its objectives, constraints and patient rights * The patient has given free and informed consent and signed the consent * Patient affiliated with or beneficiary of a health insurance plan * Patient available for 36 months of follow-up * The patient has had a stroke (within the past 10 days, diagnosis confirmed by MRI with a diffusion sequence) or transient ischemic attack (within the past 10 days, ABCD2 score greater than 3) without haemorrhage Exclusion Criteria: * The patient is currently participating in or has participated in another biomedical research study within the past three months or is currently in an exclusion period determined by a previous study. * Patient under guardianship or judicial protection * Refusal to sign the consent * Inability to correctly inform the patient or his/her trusted person about the study * The patient is pregnant, parturient, or breastfeeding * The patient has a contraindication for a treatment used in this study * Known allergy to contrast medium or severe allergy to iodine * Known active malignancy or history of cancer treatment * The patient has already undergone a full body scanner in the previous three months * Renal failure with creatinine clearance below 60 ml / min * Monoclonal immunoglobulin * History of severe symptomatic cardiovascular event (myocardial infarction, aortic dissection, mesenteric ischemia, renal ischemia) * Emergency situations that hamper the planned course of the study